Once-weekly survodutide linked to drop in body weight in obesity

MedicalXpress | يون 10, 2026

For adults with obesity without diabetes, once-weekly survodutide, an investigational glucagon receptor-glucagon-like peptide-1 receptor dual agonist, is associated with greater reductions in body weight than placebo, according to a study published online June 7 in the New England Journal of Medicine to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.